Page last updated: 2024-10-28

ibuprofen and Apoplexy

ibuprofen has been researched along with Apoplexy in 20 studies

Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine

Research Excerpts

ExcerptRelevanceReference
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever."9.10Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003)
"The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure."7.96Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020)
" We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial."7.83Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016)
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days."7.71PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002)
" Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter."6.73Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008)
" In a previous randomized trial we observed that treatment with high-dose acetaminophen (paracetamol) led to a reduction of body temperature in patients with acute ischemic stroke, even when they had no fever."5.10Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, LJ; Koudstaal, PJ; Meijer, RJ; van Breda, EJ; van der Worp, HB; van Gemert, HM, 2003)
"Overall, the use of NSAIDs is not associated with an increased risk of hemorrhagic stroke, although this risk was modestly significantly elevated in diclofenac and meloxicam users."4.93Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ( Matteson, EL; Thongprayoon, C; Ungprasert, P, 2016)
"The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure."3.96Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen. ( Berlin, JA; Fife, D; Ryan, PB; Schuemie, MJ; Swerdel, J; Weinstein, RB, 2020)
" We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial."3.83Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. ( Amarenco, P; Bousser, MG; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Gonzalez-Valcarcel, J; Hennerici, MG; Labreuche, J; Mattle, HP; Rothwell, PM; Sissani, L; Steg, PG; Vicaut, E, 2016)
" High-dose ibuprofen and diclofenac were associated with increased risk of ischemic stroke [hazard ratio 2·15 (95% confidence interval 1·66-2·79) and 2·37 (confidence interval 1·99-2·81), respectively]."3.80Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. ( Andersson, C; Fosbøl, EL; Gislason, GH; Kober, L; Olesen, JB; Olsen, AM; Torp-Pedersen, C, 2014)
"This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease."3.77Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."3.75Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)
"To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population."3.74Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007)
"Seventy-five (3 x 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days."3.71PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]. ( Dippel, DW; Kappelle, J; Koudstaal, PJ; Meijer, R; van Breda, EJ; van der Worp, B; van Gemert, M, 2002)
" Ten normal volunteer subjects underwent 3 randomized treatment sessions: aspirin 325 mg alone, ibuprofen 400 mg alone, and ibuprofen 400 mg, followed by dosing with aspirin 325 mg 2 hours thereafter."2.73Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. ( Bates, V; Gengo, FM; Gengo, MF; Mager, DE; Rainka, M; Robson, M; Rubin, L, 2008)
"Fever in acute stroke is associated with poor prognosis, but evidence-based recommendations on antipyretic therapy are lacking."1.36[Antipyretic strategies for acute stroke: a nationwide survey among German stroke units]. ( Beck, A; Kallmünzer, B; Kollmar, R; Schwab, S, 2010)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (40.00)29.6817
2010's11 (55.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Weinstein, RB1
Ryan, PB1
Berlin, JA1
Schuemie, MJ1
Swerdel, J1
Fife, D1
Chen, YR1
Hsieh, FI1
Chang, CC1
Chi, NF1
Wu, HC1
Chiou, HY1
Bhala, N1
Emberson, J1
Merhi, A1
Abramson, S1
Arber, N1
Baron, JA1
Bombardier, C1
Cannon, C1
Farkouh, ME1
FitzGerald, GA1
Goss, P1
Halls, H1
Hawk, E1
Hawkey, C1
Hennekens, C1
Hochberg, M1
Holland, LE1
Kearney, PM1
Laine, L1
Lanas, A1
Lance, P1
Laupacis, A1
Oates, J1
Patrono, C1
Schnitzer, TJ1
Solomon, S1
Tugwell, P1
Wilson, K1
Wittes, J1
Baigent, C1
Greifzu, F2
Pielecka-Fortuna, J1
Kalogeraki, E1
Krempler, K1
Favaro, PD1
Schlüter, OM1
Löwel, S2
Ungprasert, P1
Matteson, EL1
Thongprayoon, C1
Gonzalez-Valcarcel, J1
Sissani, L1
Labreuche, J1
Bousser, MG1
Chamorro, A1
Fisher, M1
Ford, I1
Fox, KM1
Hennerici, MG1
Mattle, HP1
Rothwell, PM1
Steg, PG1
Vicaut, E1
Amarenco, P1
Iannuccelli, C1
Di Franco, M1
Pulcinelli, FM1
Den Hertog, HM1
van der Worp, HB2
Tseng, MC1
Dippel, DW3
Ray, WA1
Varas-Lorenzo, C2
Chung, CP1
Castellsague, J2
Murray, KT1
Stein, CM1
Daugherty, JR1
Arbogast, PG1
García-Rodríguez, LA1
Kallmünzer, B1
Beck, A1
Schwab, S1
Kollmar, R1
Bavry, AA1
Khaliq, A1
Gong, Y1
Handberg, EM1
Cooper-Dehoff, RM1
Pepine, CJ1
Schmidt, S1
Schmidt, KF1
Kreikemeier, K1
Witte, OW2
Jablonka, JA1
Kossut, M1
Liguz-Lecznar, M1
Fosbøl, EL1
Olsen, AM1
Olesen, JB1
Andersson, C1
Kober, L1
Torp-Pedersen, C1
Gislason, GH1
van Breda, EJ2
van Gemert, HM1
Meijer, RJ1
Kappelle, LJ1
Koudstaal, PJ2
Maguire, A1
Perez-Gutthann, S1
Gengo, FM1
Rubin, L1
Robson, M1
Rainka, M1
Gengo, MF1
Mager, DE1
Bates, V1
Schafer, A1
van der Worp, B1
van Gemert, M1
Meijer, R1
Kappelle, J1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators[NCT03664466]0 participants (Actual)Interventional2021-04-29Withdrawn (stopped due to Inadequate funding)
Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration[NCT02380001]Phase 460 participants (Actual)Interventional2015-01-31Completed
Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.[NCT01910116]Phase 2/Phase 3220 participants (Actual)Interventional2013-09-30Completed
Effects on Omission of NSAIDs on the Consumption of Opioids in the Standard Analgesic Regimen After Elective Laparoscopic Colorectal Cancer Resection in an ERAS Setting. A Retrospective Single-center Cohort Study.[NCT04448652]502 participants (Actual)Observational [Patient Registry]2015-01-01Completed
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUSCAN Function Change at 12 Weeks From Baseline

"Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Median)
Shinbaro-11
Placebo-2.9

AUSCAN Function Change at 16 Weeks From Baseline

"Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

Interventionunits on a scale (Median)
Shinbaro-9.9
Placebo-4.8

AUSCAN Function Change at 4 Weeks From Baseline

"Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 4 weeks

Interventionunits on a scale (Median)
Shinbaro-6.8
Placebo-3.7

AUSCAN Function Change at 8 Weeks From Baseline

"Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks

Interventionunits on a scale (Median)
Shinbaro-9.7
Placebo-4.8

AUSCAN Pain Change at 4 Weeks From Baseline

"Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).~AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Median)
Shinbaro-9.0
Placebo-2.2

AUSCAN Pain Score at 12 Weeks From Baseline

"Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Median)
Shinbaro-14.6
Placebo-8.0

AUSCAN Pain Score at 16 Weeks From Baseline

"Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

Interventionunits on a scale (Median)
Shinbaro-15.6
Placebo-4.4

AUSCAN Pain Score at 8 Weeks From Baseline

"Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 8 weeks

Interventionunits on a scale (Median)
Shinbaro-13.4
Placebo-2.2

AUSCAN Stiffness at 12 Weeks Change From Baseline

"Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Basline and 12 weeks

Interventionunits on a scale (Median)
Shinbaro-14.0
Placebo-11.0

AUSCAN Stiffness at 16 Weeks Change From Baseline

"Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline, 16 weeks

Interventionunits on a scale (Median)
Shinbaro-10.0
Placebo-8.0

AUSCAN Stiffness at 4 Weeks Change From Baseline

"Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Median)
Shinbaro-9.0
Placebo-6.0

AUSCAN Stiffness at 8 Weeks Change From Baseline

"Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 8 weeks

Interventionunits on a scale (Median)
Shinbaro-12.0
Placebo-6

Number of OMERACT-OARSI Responder

Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baselie and 16 weeks

Interventionparticipants (Number)
Shinbaro55
Placebo40

Patient Global Assessment, Change From Baseline

"Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Median)
Shinbaro-11.0
Placebo-6.0

Patient Global Assessment, Change From Baseline

"Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

Interventionunits on a scale (Median)
Shinbaro-10.0
Placebo-8.5

Patient Global Assessment, Change From Baseline

"Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Median)
Shinbaro-9.0
Placebo-3.0

Patient Global Assessment, Change From Baseline

"Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks

Interventionunits on a scale (Median)
Shinbaro-10.0
Placebo-6.0

Physician Global Assessment, Change From Baseline

"Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Median)
Shinbaro-19.0
Placebo-13

Physician Global Assessment, Change From Baseline

"Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

Interventionunits on a scale (Median)
Shinbaro-12
Placebo-6.5

Physician Global Assessment, Change From Baseline

"Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: baseline and 4 weeks

Interventionunits on a scale (Median)
Shinbaro-12
Placebo-7.0

Physician Global Assessment, Change From Baseline

"Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks

Interventionunits on a scale (Median)
Shinbaro-16.0
Placebo-11.5

Swollen Joint Count, Change From Baseline

"Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks

InterventionJoints (Median)
Shinbaro0
Placebo0

Swollen Joint Count, Change From Baseline

"Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

InterventionJoints (Median)
Shinbaro0
Placebo0

Swollen Joint Count, Change From Baseline

"Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks

InterventionJoints (Median)
Shinbaro0
Placebo0

Swollen Joint Count, Change From Baseline

"Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks

InterventionJoints (Median)
Shinbaro0
Placebo0

Tender Joint Count, Change From Baseline

"Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 12 weeks

Interventionjoints (Median)
Shinbaro-2.0
Placebo-1.0

Tender Joint Count, Change From Baseline

"Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 16 weeks

Interventionjoints (Median)
Shinbaro-2.0
Placebo-1.0

Tender Joint Count, Change From Baseline

"Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 4 weeks

Interventionjoints (Median)
Shinbaro-1
Placebo0

Tender Joint Count, Change From Baseline

"Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..~Negative value means improvement from baseline~Positive value means deterioration from baseline" (NCT01910116)
Timeframe: Baseline and 8 weeks

InterventionJoints (Median)
Shinbaro-1.0
Placebo-1.0

Acetaminophen Rescue

yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 12 weeks and 16 weeks

,
Interventionparticipants (Number)
yesno
Placebo2104
Shinbaro4105

Acetaminophen Rescue

yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 4 weeks and 8 weeks

,
Interventionparticipants (Number)
yesno
Placebo799
Shinbaro1099

Acetaminophen Rescue

yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: 8 weeks and 12 weeks

,
Interventionparticipants (Number)
yesno
Placebo4102
Shinbaro4105

Acetaminophen Rescue

yes = AAP rescue use, no = no AAP rescue use (NCT01910116)
Timeframe: Baseline 4 weeks

,
Interventionparticipants (Number)
yesno
Placebo4102
Shinbaro7102

Number of OMERACT-OARSI Responder

Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 12 weeks

,
Interventionparticipants (Number)
respondernonresponder
Placebo4363
Shinbaro6247

Number of OMERACT-OARSI Responder

Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 8 weeks

,
Interventionparticipants (Number)
respondernonresponder
Placebo3868
Shinbaro5653

Number of OMERACT-OARSI Responder

Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment (NCT01910116)
Timeframe: Baseline and 4 weeks

,
Interventionparticipants (Number)
ResponderNonresponder
Placebo3274
Shinbaro4861

Reviews

3 reviews available for ibuprofen and Apoplexy

ArticleYear
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Lancet (London, England), 2013, Aug-31, Volume: 382, Issue:9894

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Vessels; Coronary Disease; Cyclooxygenase 2 Inhibitor

2013
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
    Stroke, 2016, Volume: 47, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprof

2016
Cooling therapy for acute stroke.
    The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1

    Topics: Acetaminophen; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dipyrone; Humans; Hypothermia

2009

Trials

2 trials available for ibuprofen and Apoplexy

ArticleYear
Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690].
    BMC cardiovascular disorders, 2003, Feb-06, Volume: 3

    Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida

2003
Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:1

    Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cross-Over S

2008

Other Studies

15 other studies available for ibuprofen and Apoplexy

ArticleYear
Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.
    Drug safety, 2020, Volume: 43, Issue:9

    Topics: Acetaminophen; Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Ag

2020
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
    The American journal of cardiology, 2018, 05-15, Volume: 121, Issue:10

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;

2018
Environmental enrichment extends ocular dominance plasticity into adulthood and protects from stroke-induced impairments of plasticity.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jan-21, Volume: 111, Issue:3

    Topics: Animals; Diazepam; Dominance, Ocular; Environment; Female; GABA Modulators; Ibuprofen; Interneurons;

2014
Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke.
    Stroke, 2016, Volume: 47, Issue:4

    Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Brain Ischemia; Cardiovascular Diseases; Female; Hemo

2016
Letter by Iannuccelli et al Regarding Article, "Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke".
    Stroke, 2016, Volume: 47, Issue:9

    Topics: Acetaminophen; Brain Ischemia; Hemorrhage; Humans; Ibuprofen; Stroke

2016
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C

2009
[Antipyretic strategies for acute stroke: a nationwide survey among German stroke units].
    Der Nervenarzt, 2010, Volume: 81, Issue:6

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Cryotherapy; Data Collection; Dipyrone; Germany; Hospitals,

2010
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
    The American journal of medicine, 2011, Volume: 124, Issue:7

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec

2011
Global impairment and therapeutic restoration of visual plasticity mechanisms after a localized cortical stroke.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Sep-13, Volume: 108, Issue:37

    Topics: Animals; Cerebrum; Dominance, Ocular; Ibuprofen; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity

2011
Experience-dependent brain plasticity after stroke: effect of ibuprofen and poststroke delay.
    The European journal of neuroscience, 2012, Volume: 36, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Cortex; Cyclooxygenase 2; Ibuprofen; Male

2012
Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:7

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Cohort Studies; Denmark; Diclofenac;

2014
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D

2007
Take aspirin before ibuprofen, not after.
    Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Administration Schedule; Drug Interactions; H

2006
My doctor recently recommended that I take low-dose aspirin to minimize the risk of a heart attack or stroke. I routinely take ibuprofen for arthritis pain. Do I need both, and is it safe to combine the two?
    Health news (Waltham, Mass.), 2000, Volume: 6, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Interactions; Humans; Ibuprofen; Myocardial I

2000
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690].
    BMC cardiovascular disorders, 2002, Mar-27, Volume: 2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Clinical Trials, Phase II

2002